Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth?

Breast

Volumn 22, Issue 6, 2013, Pages 1026-1033

  Chiorean, Roxana ^a,b,d   Braicu, Cornelia ^b,c,d   Berindan Neagoe, Ioana ^b,c,d  

^a Clinical Universitary Hospital of Dermatovenereology   (Romania)

^b UNIVERSITY OF FREIBURG   (Germany)

^c IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

Author keywords

Molecular markers; Outcome; Resistance to chemotherapy; Triple negative breast cancer

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ANDROGEN RECEPTOR; BICALUTAMIDE; CETUXIMAB; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 7; CYTOKERATIN 8; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCOSE TRANSPORTER 1; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M3; GLUTATHIONE TRANSFERASE P1; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90 INHIBITOR; MYOSIN; NERVE CELL ADHESION MOLECULE; OLAPARIB; RHO FACTOR; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN; VASCULOTROPIN; VELIPARIB; VIMENTIN;

AGE DISTRIBUTION; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; CANCER CLASSIFICATION; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; DISEASE MARKER; DNA MICROARRAY; DOWN REGULATION; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; GLUCONEOGENESIS; GLYCOLYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; MICROARRAY ANALYSIS; MOLECULAR DIAGNOSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; TISSUE REGENERATION; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION;

MOLECULAR MARKERS; OUTCOME; RESISTANCE TO CHEMOTHERAPY; TRIPLE NEGATIVE BREAST CANCER;

EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HUMANS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84887184189     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.08.007     Document Type: Review

References (84)

1. Carey L., Winer E., Viale G., Cameron D., Gianni L. Triple-negative breast cancer: disease entity or title of convenience?. Nat Rev Clin Oncol 2010, 7:683-692.
2. Penault-Llorca F., Viale G. Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Ann Oncol 2012, 23(Suppl.6):vi19-vi22.
3. Chen J.Q., Russo J. ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta 2009, 1796:162-175.
4. McNamara K.M., Yoda T., Takagi K., et al. Androgen receptor in triple negative breast cancer. JSteroid Biochem Mol Biol 2013 Jan, 133:66-76.
5. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 2012, 23(Suppl.6):7-12.
6. O'Toole S.A., Beith J.M., Millar E.K., et al. Therapeutic targets in triple negative breast cancer. JClin Pathol 2013, 66:530-542.
7. Stagg J., Allard B. Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol 2013, 5:169-181.
8. Lehmann B.D., Bauer J.A., Chen X., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. JClin Invest 2011, 121:2750-2767.
9. Bosch A., Eroles P., Zaragoza R., Viña J.R., Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 2010, 36:206-215.
10. Anders C., Carey L. Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 2008, 22:1233-1243. http://www.ncbi.nlm.nih.gov/pubmed?term=%2522Boyd%2520ZS%2522%255BAuthor%255D.
11. Gluz O., Liedtke C., Gottschalk N. Triple-negative breast cancer-current status and future directions. Ann Oncol 2009, 20:1913-1927.
12. Perou C. Molecular stratification of triple-negative breast cancers. The Oncologist 2010, 15:39-48.
13. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
14. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
15. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
16. Chen X., Li J., Gray W.H., et al. TNBCtype: a subtyping tool for triple-negative breast cancer. Cancer Inform 2012, 11:147-156.
17. Sarrió D., Rodriguez-Pinilla S.M., Hardisson D., et al. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008, 68:989-997.
18. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. NEngl J Med 2010, 363:1938-1948.
19. Zhou C., Nitschke A.M., Xiong W., et al. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res 2008, 10:R105.
20. Kong C., Wang C., Wang L., et al. NEDD9 is a positive regulator of epithelial mesenchymal transition and promotes invasion in aggressive breast cancer. PLoS One 2011, 6:e22666.
21. Seki H., Hayashida T., Jinno H., et al. HOXB9 expression promoting tumor cell proliferation and angiogenesis is associated with clinical outcomes in breast cancer patients. Ann Surg Oncol 2012, 19:1831-1840.
22. Zeng Q., Li W., Lu D., et al. CD146, an epithelial mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc Natl Acad Sci U S A 2012, 109:1127-1132.
23. Rose A.A., Annis M.G., Dong Z., et al. ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domainwith angiogenic properties. PLoS One 2010, 5:e12093.
24. Jain R.K. Molecular regulation of vessel maturation. Nat Med 2003, 9:685-693.
25. Li C., Li R., Song H., et al. Significance of AEG-1 expression in correlation with VEGF, microvessel density and clinicopathological characteristics in triple-negative breast cancer. JSurg Oncol 2011, 103:184-192.
26. Li L.Q., Min L.S., Jiang Q., et al. Progranulin expression in breast cancer with different intrinsic subtypes. Pathol Res Pract 2012, 208:210-216.
27. Witters L., Scherle P., Friedman S., et al. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res 2008, 68:7083-7089.
28. Curigliano G., Pivot X., Cortes J., et al. Arandomized phase II study of sunitinib vs.standard of care for patients with previously treated advanced triple-negative breast cancer. Cancer Res 2010, 70. [Abstr P6-12-02, presented data-SABCS 2010].
29. Gelmon K., Dent R., Mackey J.R., Laing K., McLeod D., Verma S. Targeting triple negative breast cancer: optimising therapeutic outcomes. Ann Oncol 2012, 23:2223-2234.
30. De Laurentiis M., Cianniello D., Caputo R., et al. Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev 2010, 36(Suppl.3):S80-S86.
31. Rakha E.A., Ellis I.O. Triple-negative/basal-like breast cancer: review. Pathology 2009, 41:40-47.
32. Yamamoto Y., Iwase H. Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol 2010, 15:341-351.
33. Criscitiello C., Azim H.A., Schouten P.C., Linn S.C., Sotiriou C. Understanding the biology of triple-negative breast cancer. Ann Oncol 2012, 23(Suppl.6):3-8.
34. Kreike B., van Kouwenhove M., Horlings H., et al. Gene expression profiling and histopathological characterization of triplenegative/basal-like breast carcinomas. Breast Cancer Res 2007, 9:R65.
35. Linn S.C., Van't Veer L.J. Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. Eur J Cancer 2009, 45:11-26.
36. Tao Y., Mao J., Zhang Q., Li L. Overexpression of Hedgehog signaling molecules and its involvement in triple-negative breast cancer. Oncol Lett 2011, 2:995-1001.
37. Airley R.E., Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 2007, 53:233-256.
38. Neubauer H., Clare S.E., Wozny W., et al. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. Breast Cancer Res 2008, 10:R85.
39. Billar J.A., Dueck A.C., Stucky C.C., et al. Triple-negative breast cancers: unique clinical presentations and outcomes. Ann Surg Oncol 2010, 17:384-390.
40. Park Y.H., Lee S.J., Cho E.Y., et al. Clinical relevance of TNM staging system according to breast cancer subtypes. Ann Oncol 2011, 22:1554-1560.
41. Peddi P.F., Ellis M.J., Ma C. Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer 2012, 2012:217185.
42. Flowers A., Chu Q.D., Panu L., et al. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome. Surgery 2009, 146:220-226.
43. Yaman S., Gumuskaya B., Ozkan C., et al. Lymphatic and capillary invasion patterns in triple negative breast cancer. Am Surg 2012, 78:1238-1242.
44. Mohammed R.A., Ellis I.O., Mahmmod A.M., et al. Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance. Mod Pathol 2011, 24:774-785.
45. Sun B., Zhang S., Zhang D., et al. Identification of metastasis-related proteins and their clinical relevance to triple-negative human breast cancer. Clin Cancer Res 2008, 14:7050-7059.
46. Ha N.H., Nair V.S., Reddy D.N., et al. Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res 2011, 71:7259-7269.
47. Perentes J.Y., Kirkpatrick N.D., Nagano S., et al. Cancer cell-associated MT1-MMP promotes blood vessel invasion and distant metastasis in triple-negative mammary tumors. Cancer Res 2011, 71:4527-4538.
48. Chen H.W., Du C.W., Wei X.L., Khoo U.S., Zhang G.J. Cytoplasmic CXCR4 high-expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancer. Curr Mol Med 2013 Jan 15, 13(3):410-416.
49. Cimino-Mathews A., Hicks J.L., Illei P.B., et al. Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy. Hum Pathol 2012, 43:1003-1011.
50. Zhao H., Cui K., Nie F., et al. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an invivo analysis intriple-negative breast cancer models. Breast Cancer Res Treat 2012, 131:425-436.
51. Adamo B., Deal A.M., Burrows E., et al. Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. Breast Cancer Res 2011, 13:R125.
52. Lee L.J., Alexander B., Schnitt S.J., et al. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer 2011, 117:3093-3100.
53. Palmieri D., Lockman P.R., Thomas F.C., et al. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res 2009, 15:6148-6157.
54. Amemiya Y., Yang W., Benatar T., et al. Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors. Breast Cancer Res Treat 2011, 126:373-384.
55. Yonemori K., Tsuta K., Ono M., et al. Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer 2010, 116:302-308.
56. Roberti M.P., Arriaga J.M., Bianchini M., et al. Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice. Cancer Biol Ther 2012, 13:1123-1140.
57. Greenwood C., Metodieva G., Al-Janabi K., et al. Stat1 and CD74 overexpression is co-dependent and linked to increased invasion and lymph node metastasis intriple-negative breast cancer. JProteomics 2012, 75:3031-3040.
58. Tawfik K., Kimler B.F., Davis M.K., Fan F., Tawfik O. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors. Hum Pathol 2012, 43:23-30.
59. Peng Y. Potential prognostic tumor biomarkers in triple-negative breast carcinoma. Beijing Da Xue Xue Bao 2012, 44:666-672.
60. Di Bonito M., Cantile M., Collina F., et al. Overexpression of cell cycle progression inhibitor geminin is associated with tumor stem-like phenotype of triple-negative breast cancer. JBreast Cancer 2012, 15:162-171.
61. Liu H.T., Ma R., Yang Q.F., Du G., Zhang C.J. Lymphangiogenic characteristics of triple negativity in node-negative breast cancer. Int J Surg Pathol 2009, 17:426-431.
62. Duffy M.J., McGowan P.M., Crown J. Targeted therapy for triple-negative breast cancer: where are we?. Int J Cancer 2012, 131:2471-2477.
63. Ibrahim Y.H., García-García C., Serra V., et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2012, 2:1036-1047.
64. Petrelli F., Cabiddu M., Ghilardi M., Barni S. Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?. Expert Opin Investig Drugs 2009, 18:1467-1477.
65. Isakoff S.J. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 2010, 16:53-61.
66. Takimoto C.H., Calvo E. Principles of Oncologic Pharmacotherapy. Cancer management: a multidisciplinary approach 2008, 11th ed. R. Pazdur, L.D. Wagman, K.A. Camphausen, W.J. Hoskins (Eds.).
67. Arslan C., Dizdar O., Altundag K. Pharmacotherapy of triple-negative breast cancer. Expert Opin Pharmacother 2009, 10:2081-2093.
68. Cho E.Y., Chang M.H., Choi Y.L., et al. Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC). Cancer Chemother Pharmacol 2010, 68(3):753-761.
69. Wang X., Chao L., Ma G., et al. Increased expression of osteopontin in patients with triple-negative breast cancer. Eur J Clin Invest 2008, 38:438-446.
70. Rody A., Karn T., Liedtke C., et al. Aclinically relevant gene signature in triple negative and basal like breast cancer. Breast Cancer Res 2011, 13:R97.
71. Sullu Y., Demirag G.G., Yildirim A., Karagoz F., Kandemir B. Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast. Pathol Res Pract 2011, 207:747-753.
72. Thike A.A., Iqbal J., Cheok P.Y., et al. Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. Am J Surg Pathol 2010, 34:956-964.
73. Walter O., Prasad M., Lu S., et al. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Hum Pathol 2009, 40:1528-1533.
74. Piras F., Ionta M.T., Lai S., et al. Nestin expression associates with poor prognosis and triple negative phenotype in locally advanced (T4) breastcancer. Eur J Histochem 2011, 55:e39.
75. Resetkova E., Reis-Filho J.S., Jain R.K., et al. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat 2010, 123:97-108.
76. Chekhun V.F., Zhylchuk V.E., Lukyanova N.Y., et al. Expression of drug resistance proteins in triple-receptor-negative tumors as the basis of individualized therapy of the breast cancer patients. Exp Oncol 2009, 31:123-124.
77. Zhou F.F., Yan M., Guo G.F., et al. Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells. Med Oncol 2011, 28:1302-1307.
78. Bauer J.A., Chakravarthy A.B., Rosenbluth J.M., et al. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors frompatients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res 2010, 16:681-690.
79. Nolen B.M., Marks J.R., Ta'san S., et al. Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res 2008, 10:R45.
80. Giricz O., Calvo V., Pero S.C., Krag D.N., Sparano J.A., Kenny P.A. GRB7 is required for triple-negative breast cancer cell invasion and survival. Breast Cancer Res Treat 2012, 133:607-615.
81. Ivanov O., Chen F., Wiley E.L., et al. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2008, 111:411-417.
82. Alli E., Sharma V.B., Sunderesakumar P., Ford J.M. Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 2009, 69:3589-3596.
83. Anders C.K., Winer E.P., Ford J.M., et al. PARP inhibition: "Targeted" therapy for triple negative breast cancer. Clin Cancer Res 2010, 16:4702-4710.
84. Graham T.R., Yacoub R., Taliaferro-Smith L., et al. Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells. Breast Cancer Res Treat 2010, 123:139-147.